WO2003020257A3 - USE OF β-ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - Google Patents

USE OF β-ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES Download PDF

Info

Publication number
WO2003020257A3
WO2003020257A3 PCT/EP2002/009369 EP0209369W WO03020257A3 WO 2003020257 A3 WO2003020257 A3 WO 2003020257A3 EP 0209369 W EP0209369 W EP 0209369W WO 03020257 A3 WO03020257 A3 WO 03020257A3
Authority
WO
WIPO (PCT)
Prior art keywords
adrenoceptor agonists
treatment
neurodegenerative diseases
nerve cells
cells
Prior art date
Application number
PCT/EP2002/009369
Other languages
German (de)
French (fr)
Other versions
WO2003020257A2 (en
Inventor
Josef Krieglstein
Carsten Culmsee
Vera Junker
Helmut Blum
Wolfgang Greb
Original Assignee
Eucro Europe Contract Res Gmbh
Josef Krieglstein
Carsten Culmsee
Vera Junker
Helmut Blum
Wolfgang Greb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10142176A external-priority patent/DE10142176A1/en
Priority claimed from DE10142178A external-priority patent/DE10142178A1/en
Priority claimed from DE10142175A external-priority patent/DE10142175A1/en
Priority claimed from DE10149611A external-priority patent/DE10149611A1/en
Application filed by Eucro Europe Contract Res Gmbh, Josef Krieglstein, Carsten Culmsee, Vera Junker, Helmut Blum, Wolfgang Greb filed Critical Eucro Europe Contract Res Gmbh
Priority to JP2003524566A priority Critical patent/JP2005505548A/en
Priority to AU2002333510A priority patent/AU2002333510A1/en
Priority to US10/488,500 priority patent/US20040248984A1/en
Priority to EA200400356A priority patent/EA200400356A1/en
Priority to EP02797607A priority patent/EP1420772A2/en
Publication of WO2003020257A2 publication Critical patent/WO2003020257A2/en
Publication of WO2003020257A3 publication Critical patent/WO2003020257A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)

Abstract

The invention relates to the use of β-adrenoceptor agonists for restoring and/or maintaining the function of partially or fully damaged/degenerated cells of the central nervous system and/or other nerve cells. Using β2-adrenoceptor agonists enables astrocytes to be activated and endogenous neuroprotection processes to be stimulated, whereby the damage or destruction of nerve cells can be reduced and even prevented in some cases.
PCT/EP2002/009369 2001-08-29 2002-08-22 USE OF β-ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES WO2003020257A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2003524566A JP2005505548A (en) 2001-08-29 2002-08-22 Methods of using β-adrenergic receptor antagonists for the treatment of neurodegenerative diseases
AU2002333510A AU2002333510A1 (en) 2001-08-29 2002-08-22 Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases
US10/488,500 US20040248984A1 (en) 2001-08-29 2002-08-22 Use of $g(b)-adrenoceptor agonists for the treatment of neurodegenerative diseases
EA200400356A EA200400356A1 (en) 2001-08-29 2002-08-22 APPLICATION OF β-ADRENORECEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
EP02797607A EP1420772A2 (en) 2001-08-29 2002-08-22 Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
DE10142176.1 2001-08-29
DE10142175.3 2001-08-29
DE10142178.8 2001-08-29
DE10142176A DE10142176A1 (en) 2001-08-29 2001-08-29 Use of beta-adrenoceptor agonists, e.g. reproterol, salmeterol or terbutaline, for restoring and/or maintaining function of damaged nerve cells, e.g. for treatment of neurodegenerative diseases
DE10142178A DE10142178A1 (en) 2001-08-29 2001-08-29 Use of beta-adrenoceptor agonists, e.g. reproterol, salmeterol or terbutaline, for restoring and/or maintaining function of damaged nerve cells, e.g. for treatment of neurodegenerative diseases
DE10142175A DE10142175A1 (en) 2001-10-09 2001-08-29 Use of beta-adrenoceptor agonists, e.g. reproterol, salmeterol or terbutaline, for restoring and/or maintaining function of damaged nerve cells, e.g. for treatment of neurodegenerative diseases
DE10149611A DE10149611A1 (en) 2001-08-29 2001-10-09 Use of beta-adrenoceptor agonists, e.g. reproterol, salmeterol or terbutaline, for restoring and/or maintaining function of damaged nerve cells, e.g. for treatment of neurodegenerative diseases
DE10149611.7 2001-10-09

Publications (2)

Publication Number Publication Date
WO2003020257A2 WO2003020257A2 (en) 2003-03-13
WO2003020257A3 true WO2003020257A3 (en) 2004-01-08

Family

ID=27438007

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/009369 WO2003020257A2 (en) 2001-08-29 2002-08-22 USE OF β-ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

Country Status (5)

Country Link
EP (1) EP1420772A2 (en)
JP (1) JP2005505548A (en)
AU (1) AU2002333510A1 (en)
PL (1) PL373490A1 (en)
WO (1) WO2003020257A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1754474A1 (en) * 2005-02-02 2007-02-21 Eucro European Contract Research GmbH & Co. KG Use of S-Clenbuterol
GB0519274D0 (en) * 2005-09-21 2005-11-02 Arakis Ltd The treatment of neurodegenerative diseases
EP2007206A4 (en) * 2006-03-16 2010-12-08 Yeda Res & Dev Method and composition for protecting neuronal tissue from damage induced by elevated glutamine levels
CN101915841B (en) * 2010-07-26 2013-01-02 河南省科学院生物研究所有限责任公司 Ternary detection test bar of beta-stimulants albuterol, clenobuterol hydrochloride and ractopamine and preparation method thereof
US9265735B2 (en) 2010-11-30 2016-02-23 New York University Methods for screening to identify therapeutic agents for Alzheimer's disease and use thereof
US20140249180A1 (en) * 2011-10-03 2014-09-04 National Center For Geriatrics And Gerontology Tau aggregation inhibitor
US9907799B2 (en) 2013-04-02 2018-03-06 The Doshisha Tau aggregation inhibitor
CN115531368A (en) * 2021-06-14 2022-12-30 谭文 Application of R-carbamate-beta-phenylethanolamine compounds in treatment of learning and memory deficiency and neurodegenerative diseases
CN116236467B (en) * 2023-02-07 2023-10-27 中国人民解放军总医院 New application of simatron or derivative thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281607A (en) * 1992-10-08 1994-01-25 New York University Method of using Alpha 2-Antagonists for the Treatment of Neurodegenerative Diseases
US5958919A (en) * 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
WO2002003918A2 (en) * 2000-07-07 2002-01-17 New York Medical College Treating neural conditions resulting from spinal cord contusions and other causes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
DE10299048I2 (en) 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Use of adamantane derivatives for the prevention and treatment of cerebral ischemia
AU1731101A (en) * 1999-12-07 2001-06-18 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
ATE548048T1 (en) * 2000-06-01 2012-03-15 Childrens Medical Center ONCOMODULIN FOR THE TREATMENT OF NEUROLOGICAL DISEASES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281607A (en) * 1992-10-08 1994-01-25 New York University Method of using Alpha 2-Antagonists for the Treatment of Neurodegenerative Diseases
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
US5958919A (en) * 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
WO2002003918A2 (en) * 2000-07-07 2002-01-17 New York Medical College Treating neural conditions resulting from spinal cord contusions and other causes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ALEXANDER G M ET AL: "Beta 2-adrenergic agonist as adjunct therapy to levodopa in Parkinson's disease.", NEUROLOGY. UNITED STATES AUG 1994, vol. 44, no. 8, August 1994 (1994-08-01), pages 1511 - 1513, XP009005207, ISSN: 0028-3878 *
CULMSEE ET AL: "Neuroprotection by drug-induced growth factors", PHARMACOLOGY OF CEREBRAL ISCHEMIA, 1998, pages 333 - 348, XP000905223 *
FRERICHS O ET AL: "[The influence on nerve regeneration by the beta2-receptor agonist clenbuterol]", HANDCHIRURGIE, MIKROCHIRURGIE, PLASTISCHE CHIRURGIE: ORGAN DER DEUTSCHSPRACHIGEN ARBEITSGEMEINSCHAFT FUR HANDCHIRURGIE: ORGAN DER DEUTSCHSPRACHIGEN ARBEITSGEMEINSCHAFT FUR MIKROCHIRURGIE DER PERIPHEREN NERVEN UND GEFASSE: ORGAN DER.. GERMANY MAR 2002, vol. 34, no. 2, March 2002 (2002-03-01), pages 84 - 88, XP009005328, ISSN: 0722-1819 *
JUHASZ-POCSINE KATALIN ET AL: "Beta-2 adrenergic agonist (Albuterol) ergotropic effect on neck extension (NE) and neck flexion (NF) maximal voluntary isometric contraction (MVIC) strength in amyotrophic lateral sclerosis (ALS) patients: Quasi experimental prospective non-randomized control pilot studies using medical research cou", NEUROLOGY, vol. 52, no. 6 SUPPL. 2, 12 April 1999 (1999-04-12), 51st Annual Meeting of the American Academy of Neurology;Toronto, Ontario, Canada; April 17-24, 1999, pages A526, XP009005159, ISSN: 0028-3878 *
SEMKOVA I ET AL: "CLENBUTEROL PROTECTS MOUSE CEREBRAL CORTEX AND RAT HIPPOCAMPUS FROM ISCHEMIC DAMAGE AND ATTENUATES GLUTAMATE NEUROTOXICITY IN CULTURED HIPPOCAMPAL NEURONS BY INDUCTION OF NGF", BRAIN RESEARCH, AMSTERDAM, NL, vol. 717, no. 1 - 2, 1996, pages 44 - 54, XP000904807, ISSN: 0006-8993 *
SEMKOVA I ET AL: "NEUROPROTECTION MEDIATED VIA NEUROTROPHIC FACTORS AND INDUCTION OF NEUROTROPHIC FACTORS", BRAIN RESEARCH REVIEWS, ELSEVIER, XX, vol. 30, no. 2, August 1999 (1999-08-01), pages 176 - 188, XP000901972, ISSN: 0165-0173 *

Also Published As

Publication number Publication date
WO2003020257A2 (en) 2003-03-13
EP1420772A2 (en) 2004-05-26
AU2002333510A1 (en) 2003-03-18
PL373490A1 (en) 2005-09-05
JP2005505548A (en) 2005-02-24

Similar Documents

Publication Publication Date Title
WO2000051587A3 (en) Jak-3 inhibitors for treating allergic disorders
WO2003101397A3 (en) Tetravalent dengue vaccines
IL159109A0 (en) Beta-amino tetrahydroimidazo (1,2-a) pyrazines and tetrahydrotriazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
AU6693898A (en) Composition for the treatment of male climacteric disorders with nitric oxide s ynthase substrates and/or donors, in combination with androgens and/or arom atase inhibitors
AU3895000A (en) Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
WO2000043032A3 (en) Baff, inhibitors thereof and their use in the modulation of b-cell response
WO2001028494A3 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
AU2002339128A1 (en) Use of reelin, gas6, and protein s in the treatment of neural disorders
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
WO2002053106A3 (en) Autoantigen composition
WO2003020257A3 (en) USE OF β-ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
AU2001296014A1 (en) Agents for recoverying from or preventing fatigue in the central nerve system and foods for recoverying from or preventing fatigue
WO2000066068A3 (en) Method for inducing growth and enhancing survival of nervous tissue
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
WO2004093995A3 (en) Use of antioxidants to treat bone loss disorders
WO2002005848A3 (en) Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
WO2001015677A3 (en) Use of 5-ht1b/1d agonists to treat otic pain
ZA200400313B (en) Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine.
WO2002030354A3 (en) Uridine therapy for patients with elevated purine levels
WO2000061156A3 (en) Methods of treating schizophrenia
AU2003215190A1 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
WO2004078927A3 (en) Progenitor cells and methods of using same
MXPA02005959A (en) Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage.
WO2004019965A3 (en) Thymus-based tolerogenic approaches for type i diabetes.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CZ HU ID IL JP MX NO NZ PL RO SG SI SK UA US

Kind code of ref document: A2

Designated state(s): AU CZ HU ID IL JP MX NO NZ PL RO RU SG SI SK UA US ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI GB GR IE IT LU MC NL PT SE SK TR US

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 373490

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 2003524566

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002797607

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200400356

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2002797607

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10488500

Country of ref document: US